Fasudil, a selective Rho kinase (ROCK) inhibitor, has been shown to alleviate the severity of experimental autoimmune encephalomyelitis (EAE) via attenuating demyelination and neuroinflammation. The aim of this study was to investigate the effects of fasudil on interactions between macrophages/microglia and T cells in a mice EAE model.
Mouse BV-2 microglia were treated with IFN-γ and fasudil. Cell viability was detected with MTT assay. BV-2 microglia polarization was analyzed using flow cytometry. Cytokines and other proteins were detected with ELISA and Western blotting, respectively. Mice were immunized with MOG35–55 to induce EAE, and then treated with fasudil (40 mg/kg, ip) every other day from d 3 to d 27 pi. Encephalomyelitic T cells were prepared from the spleen of mice immunized with MOG35–55 on d 9 pi.
Treatment of mouse BV-2 microglia with fasudil (15 μg/mL) induced significant phenotype polarization and functional plasticity, shifting M1 to M2 polarization. When co-cultured with the encephalomyelitic T cells, fasudil-treated BV-2 microglia significantly inhibited the proliferation of antigen-reactive T cells, and down-regulated IL-17-expressing CD4+ T cells and IL-17 production. Furthermore, fasudil-treated BV-2 microglia significantly up-regulated CD4+CD25high and CD4+IL-10+ regulatory T cells (Tregs) and IL-10 production, suggesting that the encephalomyelitic T cells had converted to Tregs. In EAE mice, fasudil administration significantly decreased both CD11b+iNOS+ and CD11b+TNF-α+ M1 microglia, and increased CD11b+IL-10+ M2 microglia.
Fasudil polarizes BV-2 microglia into M2 cells, which convert the encephalomyelitic T cells into Tregs in the mice EAE model.
Multiple sclerosis (MS) is the most common multifocal inflammatory demyelination occurring in the white matter of the central nervous system (CNS). It is characterized by myelin sheath loss and consequent axon and neuron injury1. Experimental autoimmune encephalomyelitis (EAE) shares many pathological and histological similarities with MS and is, therefore, widely used as a preclinical model of human disease2,3. Th1 cells have been considered as primary effector T cells that participate in the pathogenetic process of MS4. Recent studies have indicated that Th17 cells are another major subtype of pathogenic T cells involved in the development of EAE5. Additionally, within the CNS, the activation and function of astrocytes and microglia are critical in the pathogenesis of EAE6,7. In chronic inflammatory pathogenesis, such as MS/EAE, a complex interplay between Th1, Th17, Th2 and regulatory T cells (Tregs) is believed to determine the outcome of the disease4. Therefore, the respective conversion of these cell populations and the discovery of novel agents that promote the expansion of beneficial cell populations may be critical to develop new therapeutic strategies against chronic inflammatory diseases such as MS.
In the CNS, microglia play essential roles in the maintenance of homeostasis and responses to neuroinflammation8,9 and are considered important contributors to tissue damage in the pathogenesis of MS/EAE for several reasons, including the following: 1) there is a strong correlation between microglia activity and both axonal injury10 and oligodendrocyte loss11; 2) microglia-conditioned medium can kill oligodendrocytes in culture12; and 3) the inhibition of macrophages/microglia activity with clodronate liposomes or genetic deletion alleviates disease severity in EAE10,13. However, in addition to these detrimental effects, microglia have beneficial roles within the CNS6,14,15. In recent years, microglia, similar to macrophages, have been subdivided into M1 and M2 phenotypes16,17. M1 microglia/macrophages are considered proinflammatory, producing proinflammatory cytokines such as TNF-α. M2 microglia/macrophages are regulatory/anti-inflammatory and secrete regulatory cytokines such as interleukin (IL)-10. The M2 subset could prominently dampen EAE severity, demonstrating a beneficial effect of the M2 phenotype18.
During the course of EAE, demyelination and axonal loss are mediated by the interplay between microglia and reactive T cells19. Upon encountering the myelin antigen, activated microglia present the antigen to T cells and trigger the re-activation of infiltrated T cells, leading to disease progression8,20. As microglia are involved in multiple stages of MS/EAE pathology, it makes microglia a potential therapeutic target to study and manipulate.
Fasudil [1-(5-isoquinolinesulfonyl)-homo-piperazine], a selective Rho kinase (ROCK) inhibitor, has been used to treat cerebral vasospasm21, stroke22, and traumatic spinal cord injury23. Our previous study showed that fasudil alleviated the severity of EAE and attenuated demyelination and neuroinflammation, acting possibly through an anti-inflammatory mechanism24. In addition, oral administration of fasudil prevented the development of EAE induced by proteolipid protein (PLP) p139-151 in SJL/J mice25. The mechanism of action might be the reduction of lymphocyte proliferation triggered by specific PLPs and the down-regulation of IL-17 levels and the IFN-γ/IL-4 ratio25. Moreover, we observed that the polarization of the M1 macrophage phenotype to the M2 phenotype in fasudil-treated EAE mice was accompanied by the inhibition of Th17 T cells and an increase in Th2 T cells26. Although several publications describe the therapeutic effects and immunological changes after fasudil treatment in EAE models, little is known regarding the immunomodulatory interaction of fasudil with microglia and T cells. In the present study, we tested the hypothesis that fasudil modifies the polarization of microglia, which further convert encephalomyelitic T cells into Tregs.
Materials and methods
Animals and ethics statement
Female C57BL/6 mice (8–10 weeks old and 18–20 g) were purchased from Vital River Laboratory Animal Technology Co Ltd, Beijing, China. The study was approved by the Ethics Committee of Shanxi Datong University, Datong, China, and it was performed in accordance with the ethical standards of the International Council for Laboratory Animal Science. All mice were housed under pathogen-free conditions and maintained in a reversed 12:12-h light/dark cycle in a temperature-controlled room (25±2 °C) for 1 week prior to experimental manipulation.
BV-2 microglial culture
The BV-2 immortalized microglial cell line27 was purchased from ShenKe Biological Technology Co, Ltd, Shanghai, China, and cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco/Life Technologies, Carlsbad, CA, USA), supplemented with 10% fetal bovine serum (FBS; Gibco/Life Technologies, Carlsbad, CA, USA), 100 U/mL penicillin and 100 μg/mL streptomycin (Gibco/Life Technologies, Carlsbad, CA, USA) at 37 °C in a humidified cell incubator. The cells were plated on 96-well, 24-well, or 6-well plates at a density of 1×106/mL for the experiments. For the subculture, the cells were removed from the culture flask, re-suspended in complete medium and sub-cultured in different plates for the experiments.
Induction of chronic EAE
Mouse myelin oligodendrocyte glycoprotein peptide35-55 (MOG35–55, MEVGWYRSPFSRVVHLYRNGK) was produced in an automatic synthesizer (CL Bio-Scientific Company, Xi-an, China). The purity of the peptide was >95% as determined by HPLC.
EAE was induced by immunization with 300 μg of MOG35–55 in Freund's complete adjuvant (Sigma, St Louis, MO, USA) supplemented with 3 mg/mL of tuberculosis H37Ra (BD Difco, Detroit, MI, USA) (400 μg/mice). Mice were intraperitoneally (ip) injected with 750 ng of pertussis toxin (Enzo Life Sciences, Farmingdale, NY, USA) on d 0 and 2 post-immunization (pi). Animals were weighed and evaluated for clinical score in a blinded fashion by at least two investigators. Clinical score of EAE was graded according to the following criteria: 0, healthy; 1, limp tail; 2, ataxia and/or paresis of hind limbs; 3, paralysis of hind limbs and/or paresis of forelimbs; 4, tetraparalysis; and 5, moribund or death.
Administration of fasudil
Mice were divided into 2 groups, the fasudil experimental group and the saline control group (n=8 in each group). Fasudil (Tianjin Chase Sun Pharmaceutical Co, Ltd, Tianjin, China) was injected ip at 40 mg·kg−1·d−1 every other day from d 3 to d 27 pi. The injection of saline was set up as a control in a similar manner.
Cell viability assay
Cell viability was detected by MTT assay. Briefly, 100 μL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (0.5 mg/mL) was added to the cultured cells and incubated for 4 h at 37 °C. After adding 100 μL DMSO, the OD value (570 nm) was detected by a Synergy H1 Hybrid reader (BioTek Instruments, Winooski, VT, USA).
Cell death was measured by lactate dehydrogenase (LDH) release. The levels of LDH in the supernatants of the cultured cells were measured with a cytotoxicity detection kit (Promega, Madison, WI, USA), according to the manufacturer's protocol. The maximum LDH release assessed by freeze-thaw lysing the normal culture cells was considered as the control value (100% LDH release). The data were expressed as the percentage of the control value.
Preparation of encephalomyelitic T cells
The encephalitogenic CD4-positive T cells specific for MOG35–55 were obtained from the spleen of mice that had been immunized with MOG35–55. The mice were immunized with MOG35–55 using the procedure used for EAE induction. On d 9 pi, the spleen was removed and the mononuclear cells were prepared. The encephalitogenic CD4-positive T cells specific for MOG35–55 were obtained with the use of anti-mouse CD4 magnetic beads (Miltenyi Biotech, Auburn, CA, USA).
Co-culture of BV-2 and encephalomyelitic T cells
The BV-2 cells were cultured in the absence or presence of IFN-γ (100 U/mL) and/or fasudil (15 μg/mL) for 72 h. Next, IFN-γ and fasudil were removed by washing with PBS before co-culturing the BV-2 cells with the encephalomyelitic T cells. The encephalomyelitic T cells were added to the BV-2 monolayer (fasudil- or PBS-treated BV-2 cells) at an estimated ratio of 5:1 in complete medium supplemented with MOG35–55 (10 μg/mL) and were maintained in co-culture for 72 h. The supernatants were collected to analyze nitric oxide and cytokines, and the cells were obtained for flow cytometric analysis.
Flow cytometric analysis
The BV-2 cells were stained with the following antibodies: PE-CD16/32, PE-CD206, PE-CCR7, PE-CD11c, PE-CD23, PE-MHC class II (eBioscience, San Diego, CA, USA), anti-iNOS and anti-arginase (BD Biosciences, Franklin Lakes, NJ, USA), followed by the corresponding PE-conjugated secondary antibodies for iNOS and arginase. The mixed cells from the co-culture were stained with the following antibody pairs: FITC-CD4 and PE-CD25 (eBioscience, San Diego, CA, USA), PE-IFN-γ, PE-IL-10, and PE-IL-17 (eBioscience, San Diego, CA, USA). The cells were gated using forward and sideward scatter characteristics for lymphocytes and monocytes, and at least 10 000 gated events were collected using flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). The data were analyzed using CellQuest software.
T cell proliferation assay
The T cells were labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE) and co-cultured with PBS- or fasudil-treated BV-2 microglia (T cells: BV-2 microglia, 5:1) in the presence of MOG35-55 (10 μg/mL). After 72 h, the number of proliferating cells was determined through CFSE dilution with flow cytometry. The data were analyzed using CellQuest software.
Cytokine ELISA assay
The supernatants of the T cell and BV-2 microglia co-culture were harvested and analyzed for the cytokine concentrations of IFN-γ, IL-10, IL-17, and TNF-α using sandwich ELISA kits (Peprotech, Rocky Hill, NJ, USA), following the manufacturer's instructions. The concentrations of the cytokines were quantified with reference to the standard curve. The measurements were performed in duplicate and repeated as 3 independent experiments. The results were expressed as pg/mL.
The mice were anesthetized and perfused with PBS and 4% buffered paraformaldehyde. Sections of the spinal cord (10 μm) were incubated with anti-CD11b (1:1000, eBioscience, San Diego, CA, USA) at 4 °C overnight and with Alexa Fluor 488-conjugated secondary antibodies (1:1000, Invitrogen, Eugene, OR, USA) at room temperature (RT) for 2 h. The slides were incubated at 4 °C overnight with anti-iNOS (1:1000, BD Biosciences, Franklin Lakes, NJ, USA), anti-TNF-α (1:500, Peprotech, Rocky Hill, NJ, USA), anti-arginase (1:1000, BD Biosciences, Franklin Lakes, NJ, USA) or anti-IL-10 (1:500, Peprotech, Rocky Hill, NJ, USA), followed by Alexa Fluor 555-conjugated secondary antibodies (1:1000, Invitrogen, Eugene, OR, USA) at RT for 2 h. As a negative control, additional sections were treated similarly, without the primary antibodies.
Western blot analysis
The BV-2 microglia were homogenized with a glass homogenizer using ice-cold lysis buffer supplemented with protease inhibitors. The protein content was quantitated using the Bradford protein assay (Sigma, St Louis, MO, USA). The lysates were loaded on SDS-polyacrylamide gels and transferred onto nitrocellulose membrane (Merck Millipore, Tullagreen Carrigtwohill, Cork, Ireland). The membranes were then incubated at 4 °C overnight with antibodies against anti-iNOS (1:1000, BD Biosciences, Franklin Lakes, NJ, USA), anti-arginase (1:1000, BD Biosciences, Franklin Lakes, NJ, USA) and anti-GAPDH (1:1000, Epitomics, Burlingame, CA, USA). Next, the membranes were incubated with the horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technology, Danvers, MA, USA) for 1 h at RT. The immunoblots were developed using an enhanced chemiluminescence (ECL) system (GE Healthcare, Buckinghamshire, UK) and analyzed using Quantity Software (Bio-Rad, Hercules, CA, USA).
Nitric oxide (NO) was assayed by measuring the end product nitrite, which was determined by a colorimeter assay based on the Griess reaction. The supernatants (100 μL) of the cultured cells were mixed with 100 μL of Griess reagent for 10 min at RT. The absorbance was measured at 510 nm. The concentrations of nitrite were determined with reference to a standard curve of sodium nitrite (Sigma, St Louis, MO, USA). The results were expressed as μmol/L.
The arginase activity was measured using the QuantiChromTM arginase assay kit (BioAssay Systems, Hayward, CA, USA) following the manufacturer's instructions. Briefly, 40 μL sample was mixed with or without (blank control) 10 μL substrate buffer at 37 °C for 2 h. In addition, 50 μL of 1 mmol/L urea standard was used to prepare the standard curve. Subsequently, 200 μL urea reagent and 10 μL substrate were added to all wells and incubated for 60 min at RT. The optical density was measured at 430 nm. The arginase activity was calculated as: (ODsample–ODblank/ODstandard–ODwater)×10.4, and expressed as U/L.
Multiple comparisons among the experimental groups were performed using ANOVA followed by post hoc tests. Comparisons between two experimental groups were made using Student's t test. P<0.05 was considered statistically significant.
The effect of fasudil on the morphology and cell viability of BV-2 microglia
Resting microglia were characterized by rounded and elongated cell bodies with irregular shape (some tripolar), whereas fasudil treatment stimulated long dendritic formations in the BV-2 microglial morphology (Figure 1A). We measured cell viability 24 h after fasudil treatment using MTT and LDH assays. No change was observed in the MTT (Figure 1B) and LDH assay results (Figure 1C) after exposure to 1, 5, and 15 μg/mL of fasudil. However, there was a marked decrease in cell viability and increase in cell death after exposure to 50 μg/mL of fasudil, indicating that a higher dose of fasudil is cytotoxic.
We further examined the morphological changes and cell viability 24 h after treating the BV-2 cells with IFN-γ (100 U/mL) and/or fasudil (15 μg/mL). As shown in Figure 1D, no obvious morphological change was observed in the BV-2 microglia treated with PBS and IFN-γ, and the fasudil treatment stimulated long dendritic formations. However, there were no differences in the cell viability after exposure to 15 μg/mL of fasudil (Figure 1E and 1F).
Fasudil shifts M1 to M2 phenotype of BV-2 microglia in vitro
To characterize the effect of fasudil on the functions of the BV-2 microglia, we first measured the polarization of the BV-2 cells with the M1 markers iNOS, MHC class II, CD11c, CCR7, and CD16/32, as well as the M2 markers arginase, CD23 and CD206 by flow cytometry. Phenotypic analysis of the BV-2 cells showed that the expression of the M1 markers iNOS, MHC class II, CD11c, and CD16/32 declined after treating the BV-2 cells with IFN-γ (100 U/mL) and fasudil (15 μg/mL), compared with that after the IFN-γ treatment (Figure 2, P<0.01, respectively). The expression of CCR7 was not significantly different among the three groups. By contrast, 3 M2 markers arginase, CD23 and CD206 were elevated after the IFN-γ plus fasudil treatment; however, only the expression of CD206 was statistically significant (Figure 2, P<0.05). The treatment of fasudil alone seemed to reduce the expression of M1 markers, such as iNOS, MHC II, and CD11c, compared with the treatment with PBS; however, only the decrease in CD11c expression was statistically significant (Figure 2, P<0.05).
Next, we attempted to define the effect of fasudil on the polarization of the BV-2 microglia using alternative assays. We measured the expression of M1 iNOS and M2 arginase in the BV-2 microglia using Western blotting. As shown in Figure 3A, the fasudil treatment significantly inhibited IFN-γ-stimulated iNOS expression (P<0.05) and slightly induced the expression of arginase. Simultaneously, we measured the levels of nitric oxide (NO) and the activity of arginase in the BV-2 cells by chemical and enzymatic assays. IFN-γ stimulated the production of NO (Figure 3B, P<0.05), but did not affect the activity of arginase. However, fasudil significantly decreased the production of NO and enhanced the activity of arginase (Figure 3B, P<0.05). In addition, we detected two representative cytokines, TNF-α for M1 microglia and IL-10 for M2 microglia, using ELISA kits. The results showed that the fasudil treatment significantly inhibited IFN-γ-stimulated TNF-α production (Figure 3B, P<0.01) and slightly increased IL-10 production (not statistically significant), compared with the IFN-γ treatment. Our results clearly indicate that the fasudil treatment can shift the BV-2 microglia from the M1 to the M2 phenotype, but primarily through suppressing the M1 phenotype and function. No difference in the above results was observed after exposure to 15 μg/mL of fasudil, compared with PBS exposure (data not shown).
Fasudil-treated BV-2 microglia induce conversion of encephalomyelitic T cells
The next question was whether the polarization of the BV-2 microglia mediated by fasudil could affect the population and function of the encephalomyelitic T cells. Fasudil-treated BV-2 cells were co-cultured with the encephalomyelitic T cells (BV-2 cells: T cells, 1:5) in the presence of MOG35–55 (10 μg/mL) for 72 h. As shown in Figure 4, the fasudil-treated BV-2 cells induced the conversion of the encephalomyelitic T cells, reflected by the up-regulation of CD4+CD25high T cells and CD4+IL-10+ T cells, and the down-regulation of CD4+IL-17+ T cells (Figure 4, P<0.05 for CD4+CD25high T cells and CD4+IL-10+ T cells; P=0.06 for CD4+IL-17+ T cells).
Next, we determined whether the fasudil-treated BV-2 microglia exert their inhibitory effect on encephalomyelitic T cell proliferation. The BV-2 cells were co-cultured with encephalomyelitic T cells labeled with CFSE for 72 h in the presence of MOG35–55 (10 μg/mL). Figure 5A showed a typical analysis of the proliferation of the CFSE-labeled T cells. Upon co-culture with the BV-2 cells treated with fasudil, the T cell proliferation was lower than that in the mixed culture of T cells and BV-2 cells treated with PBS (Figure 5A, P<0.05). As shown in Figure 5B, fasudil-treated BV-2 microglia inhibited IL-17 production by the T cells and induced them to produce IL-10, compared with the PBS-treated BV-2 microglia (Figure 5B, P<0.05). Our results define that the M2 polarization of the BV-2 microglia mediated by fasudil can convert the function of the encephalomyelitic T cells, from encephalomyelitic T cells into Tregs.
Fasudil shifts the phenotype of microglia from M1 to M2 in vivo
To confirm the effect of fasudil on microglial polarization in vivo, fasudil (40 mg·kg−1·d−1) or saline was injected ip into the EAE mice induced with MOG35–55. On d 28 pi, the expression of iNOS+ and TNF-α+ in CD11b+ microglia in the lumbar enlargement of the spinal cord of fasudil-treated mice was inhibited, compared with that in saline-injected mice, as observed using double immunohistochemistry (Figure 6, P<0.01 for iNOS and P<0.05 for TNF-α). By contrast, the mean expression of IL-10+ in the CD11b+ microglia was enhanced by the fasudil treatment (P<0.05), although the number of CD11b+arginase+ microglia was not different in saline-treated and fasudil-treated mice (Figure 6). Overall, these results clearly indicate that fasudil could convert M1 microglia to the M2 phenotype both in vitro and in vivo.
MS is a chronic, disabling neurological disease characterized by progressive autoimmune abnormality. Based on studies on the mechanism and pathogenesis, MS treatment involves 3 therapeutic approaches: 1) halting the abnormal immune response that triggers the disease process28; 2) protecting neurons from further neurodegeneration, as well as axonal damage and deficits29; and 3) repairing demyelination and restoring neuronal functions by promoting endogenous mechanisms of neuronal repair or by transplanting exogenous myelinating cells30. However, current FDA-approved treatments focus primarily on immunomodulation and are only partially effective. Thus, alternative therapeutic strategies are necessary, such as neuroprotective and neuroregeneration.
Findings in MS patients and EAE models support the hypothesis that pathogenic T cells migrate and cross the blood brain barrier (BBB), then act in concert with microglia to destroy the central myelin sheaths as well as axons, resulting in the increased degeneration of surrounding neurons31,32. However, an increasing number of studies indicate that microglia play a dual role6. Harmful effects include toxicity to neurons and oligodendrocytes, release of proteases/inflammatory cytokines/free radicals, and re-activation of T cells in the CNS. Beneficial roles include axon regeneration, remyelination, clearance of myelin debris, and the release of neurotrophic factors6. Recent research indicates that macrophages/microglia of different phenotypes display completely different biological characteristics17. In the EAE model, M1 macrophages play a major pathogenetic role in disease initiation, whereas M2 macrophages contribute to disease recovery33,34. Treatments transforming M1 to M2 macrophages remarkably reduced EAE severity in mice26, indicating that drugs that induce M2 differentiation are promising therapeutic approaches.
To date, the molecular mechanism of macrophage/microglia polarization is not fully elucidated. Several molecules may be involved in the process of macrophage/microglia polarization. NF-κB and STAT1 activation promotes M1 macrophage polarization, resulting in cytotoxic and inflammatory functions. By contrast, STAT3 and STAT6 activation results in M2 macrophage polarization and is associated with immune suppression. LPS can skew M2 type cells into the M1 type through the p38 MARK pathway35. Blocking TLR4 signaling increased the anti-inflammatory potential in LPS-stimulated BV-2 microglia36.
IL-10 activates STAT3, and there is some evidence to suggest that STAT3 may also play a role in promoting M2 macrophage polarization37. In this study, 2 molecules may be involved in shifting the M1 phenotype to M2. First, higher levels of IL-10 derived from CD4+IL-10+ T cells and M2 BV-2 cells may participate in the conversion of M1 to M2 microglia through an autocrine and/or paracrine manner. Second, the relationship between iNOS and arginase, a competitive enzyme for iNOS, may influence microglia polarization. Macrophage arginase expression is regulated in response to anti-inflammatory cytokines, such as IL-4 and IL-1038. Glatiramer acetate promotes an anti-inflammatory M2 phenotype by increased anti-inflammatory cytokine IL-10 in macrophages/microglia39,40. Arginase induced mainly by Th2 cytokines can down-regulate iNOS, exhibiting iNOS-expressing M1 cells into arginase-expressing M2 cells.
Fasudil treatment stimulated long dendritic formation on BV-2 microglia, compared with PBS or IFN-γ. Microglia are highly complex cells found in the CNS that exhibit multiple forms and functional specializations, in the form of a variety of cell shapes ranging from an amoeboid to a ramified phenotype. The morphology of microglia is closely related to their functions in the microenvironment: amoeboid, when they eliminate cell debris; ramified, when they keep their microenvironment under surveillance; and branched cytoplasmic extensions, when they make direct contact with synaptic elements to modulate activity. Ramified microglia possess a characteristic form composed of long branching processes that are highly sensitive to alterations in the local microenvironment41. The function of morphological changes induced with fasudil in BV-2 cells is further investigated, including the formation of neuron synapses and phagocytosis.
In the previous study, we explored the therapeutic effect of fasudil in EAE mice, including reduced inflammatory response and demyelination, possibly through an anti-inflammatory mechanism24,26. On the one hand, fasudil directly inhibits the infiltration of inflammatory cells into the CNS through 2 mechanisms: 1) fasudil reduces the permeability of the BBB by inhibiting occludin and claudin-5 phosphorylation42 and 2) fasudil inhibits ROCK-mediated T-cell polarization and transendothelial migration by regulating cytoskeletal dynamics and cell adhesion43. On the other hand, the administration of fasudil may inhibit the CNS inflammatory response by regulating the functional plasticity of microglia, which subsequently affects the balance between proinflammatory and regulatory T cells and finally contribute to myelin repair and inflammatory suppression. In the present study, we confirmed that fasudil converts M1 microglia, expressing iNOS and TNF-α, to M2 microglia, expressing arginase and IL-10, both in vitro and in vivo. In the mixed culture of BV-2 microglia and T cells, fasudil-treated BV-2 microglia promoted the transformation of encephalomyelitic T cells into regulatory/inhibitory T cells that did not induce the development of EAE (data not shown). Th1 and Th17 cells, the predominant immunological players during EAE/MS development44,45, are primed by CNS-specific antigens presented by antigen-presenting cells in the peripheral lymphoid organs. Next, these primed T cells cross the BBB and consequently initiate a local inflammation that impairs myelin sheaths and axons, when encountering their cognate antigen presented by CNS microglia46,47. In the present study, we provided direct evidence that fasudil converts encephalomyelitic T cells into Tregs through the polarization of M2 BV-2 cells. We speculate that an increased release of IL-10 from M2 microglia and regulatory T cells may convert encephalomyelitic T cells into Tregs via autocrine and paracrine effects. In addition, other biological factors that affect T cells are also being explored. Therefore, the M2 polarization of fasudil-stimulated BV-2 microglia may inhibit the CNS inflammatory response through 2 pathways: 1) fasudil directly results in the polarization of inflammatory microglia/macrophages to anti-inflammatory cells, both in the peripheral immune system and in the CNS microenvironment and 2) fasudil indirectly regulates T cell responses through antigen presentation of polarized microglia/macrophages.
Our data demonstrate that fasudil triggers the polarization of inflammatory M1 microglia to anti-inflammatory cells that convert encephalomyelitic T cells to Tregs. These data partially indicate that fasudil exhibits a therapeutic effect by regulating the polarization of microglia/macrophages and the balance of immune cells during the progression of EAE.
This work was supported by grants from the National Natural Science Foundation of China (No 81070957, 81371414, and 81070956).